{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:41:13Z","timestamp":1784302873285,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:italic>Acinetobacter baumannii<\/jats:italic> is a bacterial pathogen that is commonly associated with hospital-acquired illnesses. Antimicrobial drug resistance in <jats:italic>A. baumannii<\/jats:italic> includes several penicillin classes, first and second-generation cephalosporins, cephamycins, most aminoglycosides, chloramphenicol, and tetracyclines. The recent rise in multidrug-resistant <jats:italic>A. baumannii<\/jats:italic> strains has resulted in an increase in pneumoniae associated with ventilators, urinary tract infections associated with the catheter, and bloodstream infections, all of which have increased complications in treatment, cost of treatment, and death. Small compounds known as antimicrobial peptides (AMPs) are known to have damaging effects on pathogenic bacteria. To determine their antimicrobial activity, AMPs are created from proteins acquired from various sources and evaluated <jats:italic>in vitro<\/jats:italic>. In the last phase of lytic cycle, bacteriophages release hydrolytic enzymes called endolysins that cleave the host\u2019s cell wall. Due to their superior potency and specificity compared to antibiotics, lysins are used as antibacterial agents. In the present study, different types of endolysin from phages of <jats:italic>A. baumannii<\/jats:italic> were selected based on an extensive literature survey. From the PhaLP database, the sequences of the selected lysins were retrieved in FASTA format and antimicrobial peptides were found among them. With the help of available bioinformatic tools, the anti-biofilm property, anti-fungal property, cell-penetrating property, and cellular toxicity of the antimicrobial peptides were determined. Out of the fourteen antimicrobial peptides found from the eight selected endolysins of <jats:italic>A. baumannii<\/jats:italic> specific phage, eight of them has anti-biofilm property, nine of them has anti-fungal property, five of them has cell-penetrating property and all of them are non-toxic.<\/jats:p>","DOI":"10.3389\/fmed.2022.1047752","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T07:14:55Z","timestamp":1667546095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Phage derived lytic peptides, a secret weapon against Acinetobacter baumannii\u2014An in silico approach"],"prefix":"10.3389","volume":"9","author":[{"given":"Abhishek","family":"Nandy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1469-0691.2004.00942.x","article-title":"ARPAC steering group antimicrobial resistance of Acinetobacterspp Europe.","volume":"10","author":"van Looveren","year":"2004","journal-title":"Clin Microbiol Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","article-title":"Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.","volume":"48","author":"Ibrahim","year":"2021","journal-title":"Mol Biol Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1469-0691.2005.01227.x","article-title":"Clinical impact and pathogenicity of Acinetobacter.","volume":"11","author":"Joly-Guillou","year":"2005","journal-title":"Clin Microbiol Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0974-777X.68538","article-title":"Multidrug resistant Acinetobacter.","volume":"2","author":"Manchanda","year":"2010","journal-title":"J Glob Infect Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"WHO Pathogens Priority list working group. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis.","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B6","year":"2022","journal-title":"Acinetobacter in healthcare settings."},{"key":"B7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.coviro.2011.06.009","article-title":"Bacteriophages and their genomes.","volume":"1","author":"Hatfull","year":"2011","journal-title":"Curr Opin Virol."},{"key":"B8","author":"Kasman","year":"2022","journal-title":"Bacteriophages."},{"key":"B9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00705-006-0849-1","article-title":"5500 Phages examined in the electron microscope.","volume":"152","author":"Ackermann","year":"2007","journal-title":"Arch Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3382\/ps.2012-02708","article-title":"Characterization of bacteriophages virulent for Clostridium perfringens and identification of phage lytic enzymes as alternatives to antibiotics for potential control of the bacterium.","volume":"92","author":"Seal","year":"2013","journal-title":"Poult Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4161\/bact.1.1.14942","article-title":"Phages in nature.","volume":"1","author":"Clokie","year":"2011","journal-title":"Bacteriophage."},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nbt0104-31","article-title":"Old dogma, new tricks\u201321st Century phage therapy.","volume":"22","author":"Thiel","year":"2004","journal-title":"Nat Biotechnol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.","volume":"8","author":"Lin","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-394438-2.00001-3","article-title":"Phage therapy\u2013history from Twort and d\u2019Herelle through Soviet experience to current approaches.","volume":"83","author":"Chanishvili","year":"2012","journal-title":"Adv Virus Res."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/srep14802","article-title":"Mammalian Host-Versus-Phage immune response determines phage fate in vivo.","volume":"5","author":"Hodyra-Stefaniak","year":"2015","journal-title":"Sci Rep."},{"key":"B16","year":"2014","journal-title":"Bacteriophage\/Phage \u2014 Learn Science at Scitable. <email>Nature.Com<\/email>."},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.mib.2008.09.012","article-title":"Bacteriophage lysins as effective antibacterials.","volume":"11","author":"Fischetti","year":"2008","journal-title":"Curr Opin Microbiol."},{"key":"B18","year":"2022","journal-title":"Cicese.mx."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1432-1033.1976.tb10382.x","article-title":"Exo-beta-N-acetylmuramidase \u2013 A novel hexosaminidase production by Bacillus subtilis B, purification and characterization.","volume":"65","author":"Rio","year":"1976","journal-title":"Eur J Biochem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1099\/mic.0.000539","article-title":"Pseudomonas phage inhibition of Candida albicans.","volume":"163","author":"Nazik","year":"2017","journal-title":"Microbiology."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/v13071240","article-title":"PhaLP: A database for the study of phage lytic proteins and their evolution.","volume":"13","author":"Criel","year":"2021","journal-title":"Viruses."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v11020113","article-title":"Phage lytic enzymes.","volume":"11","author":"Briers","year":"2019","journal-title":"Viruses."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/21597081.2015.1062590","article-title":"Antimicrobial bacteriophage-derived proteins and therapeutic applications.","volume":"5","author":"Roach","year":"2015","journal-title":"Bacteriophage."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2147\/IDR.S332051","article-title":"Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: A review.","volume":"14","author":"Gedefie","year":"2021","journal-title":"Infect Drug Resist."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1923","DOI":"10.1128\/mbio.01923-17","article-title":"Are phage lytic proteins the secret weapon to kill Staphylococcus aureus?. Gilmore MS, ed.","volume":"9","author":"Guti\u00e9rrez","year":"2018","journal-title":"mBio."},{"key":"B26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/nsa.s325594","article-title":"Bacterial biofilm destruction: A focused review on the recent use of phage-based strategies with other antibiofilm agents.","volume":"14","author":"Amankwah","year":"2021","journal-title":"Nanotechnol Sci Appl."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00825","article-title":"Bacteriophages as weapons against bacterial biofilms in the food industry.","volume":"7","author":"Guti\u00e9rrez","year":"2016","journal-title":"Front Microbiol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03306","article-title":"Perspectives of phage therapy in non-bacterial infections.","volume":"9","author":"G\u00f3rski","year":"2019","journal-title":"Front Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/jpet.119.257113","article-title":"Pharmacokinetic and pharmacodynamic properties of drug delivery systems.","volume":"370","author":"Glassman","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006512","article-title":"From bacterial killing to immune modulation: Recent insights into the functions of lysozyme.","volume":"13","author":"Ragland","year":"2017","journal-title":"PLoS Pathog."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37194-2","article-title":"Peptidoglycan binding protein (PGBP)-modified magnetic nanobeads for efficient magnetic capturing of Staphylococcus aureus associated with sepsis in blood.","volume":"9","author":"Lim","year":"2019","journal-title":"Sci Rep."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/srep21839","article-title":"dPABBs: A novel in silico approach for predicting and designing anti-biofilm peptides.","volume":"6","author":"Sharma","year":"2016","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00323","article-title":"In silico approach for prediction of antifungal peptides.","volume":"9","author":"Agrawal","year":"2018","journal-title":"Front Microbiol."},{"key":"B34","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/bioinformatics\/btt518","article-title":"CPPpred: Prediction of cell penetrating peptides.","volume":"29","author":"Holton","year":"2013","journal-title":"Bioinformatics."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073957Link","article-title":"In silico approach for predicting toxicity of peptides and proteins.","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS One."},{"key":"B36","first-page":"277","article-title":"The antibiotic resistance crisis: Part 1: Causes and threats.","volume":"40","author":"Ventola","year":"2015","journal-title":"P T."},{"key":"B37","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/cid\/ciu392","article-title":"The future of antibiotics and resistance: A tribute to a career of leadership by John Bartlett.","author":"Spellberg","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1016\/j.postharvbio.2019.110979","article-title":"Effects of the peptide H-OOWW-NH2 and its derived lipopeptide C12-OOWW-NH2 on controlling of citrus postharvest green mold.","volume":"158","author":"Li","year":"2019","journal-title":"Postharvest Biol. Technol."},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2019.100627","article-title":"Antimicrobial peptides of the vaginal innate immunity and their role in the fight against sexually transmitted diseases.","volume":"34","author":"Madanchi","year":"2020","journal-title":"New Microb New Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mib.2016.05.016","article-title":"Anti-biofilm peptides as a new weapon in antimicrobial warfare.","volume":"33","author":"Pletzer","year":"2016","journal-title":"Curr Opin Microbiol."},{"key":"B41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2016.02.006","article-title":"New frontiers for anti-biofilm drug development.","volume":"160","author":"Ribeiro","year":"2016","journal-title":"Pharmacol Therap."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.chembiol.2014.10.009","article-title":"The host antimicrobial peptide Bac71-35 binds to bacterial ribosomal proteins and inhibits protein synthesis.","volume":"21","author":"Mardirossian","year":"2014","journal-title":"Chem Biol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00073","article-title":"Membrane active antimicrobial peptides: Translating mechanistic insights to design.","volume":"11","author":"Li","year":"2017","journal-title":"Front Neurosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1128\/AAC.49.11.4789-4792.2005","article-title":"Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats.","volume":"49","author":"Entenza","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B45","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1128\/IAI.71.11.6199-6204.2003","article-title":"Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia.","volume":"71","author":"Loeffler","year":"2003","journal-title":"Infect Immun."},{"key":"B46","first-page":"5311","article-title":"The murien hydrolase of thebacteriophage phi3626 dual lysis system is active against all testedClostridium perfringens strains.","volume":"68","author":"Zimmer","year":"2002","journal-title":"ApplEnviron Microbiol."},{"key":"B47","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1128\/JB.188.7.2711-2714.2006","article-title":"PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis.","volume":"188","author":"Yoong","year":"2006","journal-title":"J Bacteriol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1080\/14786419.2019.1641811","article-title":"An in silico approach towards identification of virulence factors in red complex pathogens targeted by reserpine.","volume":"35","author":"Ushanthika","year":"2021","journal-title":"Nat Prod Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/fmb.12.97","article-title":"Bacteriophage endolysins as novel antimicrobials.","volume":"7","author":"Schmelcher","year":"2012","journal-title":"Future Microbiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/cr00105a006","article-title":"Catalytic mechanism of enzymic glycosyl transfer.","volume":"90","author":"Sinnott","year":"1990","journal-title":"Chem Rev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1073\/pnas.69.10.2970","article-title":"A mechanism of action for carboxypeptidase A.","volume":"69","author":"Barber","year":"1972","journal-title":"Proc Natl Acad Sci."}],"updated-by":[{"DOI":"10.3389\/fmed.2025.1642178","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1047752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:41:08Z","timestamp":1751046068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1047752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":51,"alternative-id":["10.3389\/fmed.2022.1047752"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1047752","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2025.1642178","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"article-number":"1047752"}}